T

T-cell and NK cell malignancies anaplastic lymphoma large cell, 522-523 angioimmunoblastic T-cell lymphomas, 523 blastic NK-cell lymphomas, 526 enteropathy-type T-cell lymphomas, 523 extranodal of nasal type, 523-524 hepatosplenic T-cell lymphomas, 524 mycosis fungoides/Sezary syndrome, 524-525 peripheral T-cell lymphoma unspecified, 521-522 primary cutaneous CD30 positive type, 525-526 subcutaneous panniculitis like, 526 T-cell lymphomas, 497, 510

treatment approach to adult related arsenic trioxide, 662-664 chemotherapy, 657 monoclonal antibodies, 664 nucleoside analogs, 662

retroviral and immunomodulatory agents, 662 stem cell transplantation, 658-662

supportive care, 665 toposiomerase inhibitors, 664 tenofovir, 662

thalidomide, 440, 479, 491, 876 therapeutic touch, 59 thorotrast, 2

thrombocytopenia, 476, 478, 487-489, 494 thrombocytosis, 28, 475 tipifarnib, 491

topoisomerase I inhibitors, 489-490 topoisomerase II inhibitors, 3, 5, 9, 664 topotecan, 489, 492-493 t(5;12)(q33;p13) gene, 490 t(5;10)(q33;q22), 490 t(15;17)(q22;q12-21), 10

t(8;21)(q22;q22)/AML1(RUNX1)- ETO(CBFA2T1), 16-17 t(8;21)(q22;q22) gene, 10-11 tranexamic acid, 65 trapoxin, 97

treatment-related mortality (TRM), 73 triazenes, 1089 trichostatin, 97

tumor lysis syndrome (TLS), 26-27, 42, 1159-1160 tumor necrosis factor a (TNF-a), 482 tyrosine kinase inhibitors, 1105-1107

Was this article helpful?

0 0

Post a comment